Equity Overview
Price & Market Data
Price: $4.06
Daily Change: -$0.04 / 0.99%
Daily Range: $3.98 - $4.18
Market Cap: $29,077,084
Daily Volume: 31,284
Performance Metrics
1 Week: -6.79%
1 Month: -13.10%
3 Months: -2.45%
6 Months: -37.72%
1 Year: -31.97%
YTD: -40.77%
Company Details
Employees: 55
Sector: Health technology
Industry: Biotechnology
Country:
Details
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.